UroGen Pharma (URGN) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Company overview and technology

• Developed RTGel, a reverse thermal gel that enables sustained drug delivery in the bladder and upper tract, addressing unmet needs in urothelial cancer treatment.

• Two commercial assets: JELMYTO for upper tract urothelial carcinoma and ZUSDURI for low-grade, intermediate-risk non-muscle invasive bladder cancer.

• RTGel technology allows for direct, prolonged exposure of chemotherapeutic agents to tumor sites.

Market opportunity and launch dynamics

• ZUSDURI targets a market of about 60,000 recurrent, low-grade, intermediate-risk bladder cancer patients annually in the U.S., roughly 10 times the size of the initial JELMYTO market.

• Early launch revenue for ZUSDURI showed rapid growth, with October revenue ($4.5M) significantly outpacing Q3 ($1.8M), reflecting operational ramp-up.

• Permanent J-code implemented in January is accelerating uptake, reducing administrative burden and increasing physician confidence.

Clinical impact and physician feedback

• ZUSDURI demonstrated an 80% complete response rate, with 80% of those maintaining response at 12 months; 90% of patients preferred it over surgery.

• Early adopters include patients with multiple recurrences, rapid recurrences, and elderly patients with comorbidities.

• About one-third of the target population is considered high unmet need.

• Reimbursement has been robust, with no denials reported and positive feedback post-J-code.